Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer and accounts for much higher recurrence and metastasis rates. TNBCs are a specific subtype of epithelial breast tumours that are immunohistochemically negative for the protein expression of the estrogen receptor, the progesterone receptor, and lack of overexpression/gene amplification of human epidermal growth factor receptor 2 [1]. TNBC is the most lethal subtype of breast cancer owing to its high heterogeneity, aggressive nature, and lack of treatment options. This aggressive metastatic cancer contributes to the overall shortened survival of patients diagnosed with TNBC [2].
Currently, chemotherapy remains the standard of care for TNBC treatment due to the absence of molecular targets, but unfortunately, patients frequently develop resistance which underscores the need for developing novel therapeutic and preventive approaches for this disease [3]. It has become evident that the development of TNBC chemoresistance is multifaceted and based on the elaborate interplay of the tumor microenvironment, drug efflux, and cancer stem cells. Alterations of multiple signaling pathways govern these interactions [2]. Recent evidence from clinical trials and preclinical studies have demonstrated a pivotal role of the STAT3 (signal transducer and activator of transcription 3) signaling pathway in the initiation, progression, and metastasis of TNBC [3].
The aim of this study is to investigate the expression of STAT3, ALDH1A1, NFIB genes, compare it with samples before and after treatment and discuss their potential as biomarkers for therapeutic purposes.
In this study, we used quantitative PCR to determine STAT3, ALDH1A1, NFIB expression in 22 blood plasma samples of TNBC patients before treatment and 22 samples after treatment. The results revealed statistically significant differences in gene expression of STAT3 (p=0.0067) between samples before and after treatment. Furthermore, using logistic regression we determined that these three genetic biomarkers have potential to distinguish clinically significant samples before treatment from after treatment, however, more samples need to be tested to confirm the validity of the model.
In conclusion, the studied genes, especially the STAT3 oncogene, are promising targets, which may be used for further TNBC research, prevention, and therapy.